These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 8864278

  • 1. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
    Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H.
    Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
    [Abstract] [Full Text] [Related]

  • 2. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
    Peraud A, Watanabe K, Plate KH, Yonekawa Y, Kleihues P, Ohgaki H.
    J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
    [Abstract] [Full Text] [Related]

  • 3. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
    Yoon KS, Lee MC, Kang SS, Kim JH, Jung S, Kim YJ, Lee JH, Ahn KY, Lee JS, Cheon JY.
    J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
    [Abstract] [Full Text] [Related]

  • 4. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
    Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H.
    J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
    [Abstract] [Full Text] [Related]

  • 5. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
    Dong L, Pu PY, Wang H, Wang GX, Kang CS, Jiao DR.
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982
    [Abstract] [Full Text] [Related]

  • 6. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.
    Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC, Lo KW.
    J Neuropathol Exp Neurol; 1999 Feb; 58(2):120-8. PubMed ID: 10029095
    [Abstract] [Full Text] [Related]

  • 7. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.
    Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G.
    J Neuropathol Exp Neurol; 1996 Jul; 55(7):822-31. PubMed ID: 8965097
    [Abstract] [Full Text] [Related]

  • 8. Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
    Gil-Benso R, Lopez-Gines C, Benito R, López-Guerrero JA, Callaghan RC, Pellín A, Roldán P, Cerdá-Nicolas M.
    Clin Neuropathol; 2007 Jul; 26(5):224-31. PubMed ID: 17907599
    [Abstract] [Full Text] [Related]

  • 9. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    Lang FF, Miller DC, Koslow M, Newcomb EW.
    J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
    [Abstract] [Full Text] [Related]

  • 10. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
    Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H.
    J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
    [Abstract] [Full Text] [Related]

  • 11. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
    Sure U, Rüedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME.
    J Neuropathol Exp Neurol; 1997 Jul; 56(7):782-9. PubMed ID: 9210874
    [Abstract] [Full Text] [Related]

  • 12. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
    Das A, Tan WL, Teo J, Smith DR.
    J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
    [Abstract] [Full Text] [Related]

  • 13. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
    Biernat W, Kleihues P, Yonekawa Y, Ohgaki H.
    J Neuropathol Exp Neurol; 1997 Feb; 56(2):180-5. PubMed ID: 9034372
    [Abstract] [Full Text] [Related]

  • 14. Primary and secondary glioblastomas: from concept to clinical diagnosis.
    Kleihues P, Ohgaki H.
    Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
    [Abstract] [Full Text] [Related]

  • 15. Sporadic p53 mutations and absence of ras mutations in glioblastomas.
    Gömöri E, Dóczi T, Pajor L, Matolcsy A.
    Acta Neurochir (Wien); 1999 Jan; 141(6):593-9. PubMed ID: 10929724
    [Abstract] [Full Text] [Related]

  • 16. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
    Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, Ishii N, Van Meir EG.
    Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
    [Abstract] [Full Text] [Related]

  • 17. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
    Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG, Aldape K.
    Cancer Res; 2001 Feb 01; 61(3):1122-8. PubMed ID: 11221842
    [Abstract] [Full Text] [Related]

  • 18. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U.
    Acta Neuropathol; 2001 Apr 01; 101(4):311-20. PubMed ID: 11355302
    [Abstract] [Full Text] [Related]

  • 19. Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations.
    Watanabe T, Nobusawa S, Lu S, Huang J, Mittelbronn M, Ohgaki H.
    J Neuropathol Exp Neurol; 2009 Feb 01; 68(2):210-5. PubMed ID: 19151620
    [Abstract] [Full Text] [Related]

  • 20. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
    Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC.
    Brain Pathol; 1998 Oct 01; 8(4):655-67. PubMed ID: 9804374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.